Carbon Monoxide
drugOn this page
Also known as Carbon oxide (co)Carboneum oxygenisatum
Summary
Carbon Monoxide (CHEMBL1231840) is a phase-3 clinical-stage small-molecule vasodilator agent (ATC V04CX08); indicated across 6 conditions including idiopathic pulmonary fibrosis and acute respiratory distress syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- ATC class: V04CX08
- Indications: 6 conditions
- Clinical trials: 10
- Chemistry: 28.01 Da · CO
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1231840 |
| Name | Carbon Monoxide |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 281 |
| ChEBI | CHEBI:17245 |
| ATC | V04CX08 |
| Molecular formula | CO |
| Molecular weight | 28.01 |
| InChIKey | UGFAIRIUMAVXCW-UHFFFAOYSA-N |
SMILES: [C-]#[O+]
IUPAC name: carbon monoxide
ChEBI definition: A one-carbon compound in which the carbon is joined only to a single oxygen. It is a colourless, odourless, tasteless, toxic gas.
Pharmacological roles (ChEBI): neurotoxin, signalling molecule, vasodilator agent, neurotransmitter, P450 inhibitor, ligand, biomarker, probe, EC 1.9.3.1 (cytochrome c oxidase) inhibitor.
Other ChEBI roles (chemical / environmental): metabolite, human metabolite, mouse metabolite.
Also known as: Carbon monoxide, Carbon oxide (co), Carboneum oxygenisatum, CARBON MONOXIDE
Parent form; salt/anhydrous children: CHEMBL2364719
Patent coverage: 603,937 distinct patent families (1,303,901 SureChEMBL compound mentions), from 4 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| idiopathic pulmonary fibrosis | 2 | MONDO:0800504 | EFO:0000768 |
| acute respiratory distress syndrome | 2 | MONDO:0006502 | EFO:1000637 |
| chronic obstructive pulmonary disease | 2 | MONDO:0005002 | EFO:0000341 |
| adult acute respiratory distress syndrome | 2 | MONDO:0100130 | MONDO:0100130 |
| ileus | 2 | MONDO:0004567 | MONDO:0004567 |
| pulmonary arterial hypertension | 1 | MONDO:0015924 | EFO:0001361 |
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 5 |
| PHASE1 | 3 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00122694 | PHASE2 | COMPLETED | Modification of Chronic Inflammation by Inhaled Carbon Monoxide in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD) |
| NCT01523548 | PHASE1/PHASE2 | WITHDRAWN | Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension |
| NCT00094406 | PHASE1 | COMPLETED | Carbon Monoxide to Prevent Lung Inflammation |
| NCT00315965 | PHASE1 | UNKNOWN | Development of a New Method for Steady-State Measurement of NO Lung Diffusing Capacity in Healthy Subjects |
| NCT03067701 | PHASE1 | COMPLETED | Effects of Carbon Monoxide Breathing on Blood Vessel Function |
| NCT00180622 | Not specified | WITHDRAWN | Markers for Chronic Obstructive Pulmonary Disease (COPD) |
| NCT02066558 | Not specified | COMPLETED | Carbon Monoxide’s Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow |
| NCT03075020 | Not specified | COMPLETED | Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura. |
| NCT03385174 | Not specified | COMPLETED | Carbon Monoxide Headache Triggering Properties as Well as Effects on the Brain’s Vessels and Blood Flow |
| NCT04679402 | Not specified | COMPLETED | Diaphragm Function and Diver Endurance |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.